Researches – Page 64 – media

MRC links with UCB in antibody initiative

The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
- Source: pharmatimes
- 852
- August 4, 2017
antibody Company Insight Researches
UK’s University of Bristol develops new test to fight antibiotic resistance

Researchers at the University of Bristol in the UK have developed a new technology to aid general practitioners in prescribing antibiotics and to assist in fighting antibiotic resistance.
- Source: medicaldevices-network.com
- 463
- August 4, 2017
antibiotic resistance Researches
Diabetes prescriptions rocket 80 percent in a decade

Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
- Source: pharmatimes
- 554
- August 3, 2017
diabetes Market Views Researches
UC Riverside tests new biopsy device for cervical cancer

A research team at the University of California, Riverside (UC Riverside) in the US has evaluated a new device manufactured by tissue sampling devices maker Histologics.
- Source: medicaldevices-network.com
- 465
- August 3, 2017
cancer cervical Clinical Trials Researches
AZ, Merck link to develop and commercialise cancer drugs

AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
- Source: pharmatimes
- 492
- July 31, 2017
cancer Lynparza Market Views Researches therapy
ViiV’s long-acting two-drug HIV regimen hits targets

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who had already achieved viral suppression with a daily three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs). Following 96 weeks of maintenance treatment, viral suppression rates for the two-drug regimen dosed every eight weeks (94 percent) or every four weeks (87 percent) were comparable to the rate observed in patients continuing with a three-drug oral regimen (84 percent). In the study, data from which were published in The Lancet and presented at the annual conference ...
- Source: Medicaldevice-network
- 510
- July 27, 2017
Clinical Trials formulation HIV Researches
OraSure’s HIV self-test gets WHO prequalification

US-based point-of-care (POC) diagnostics developer OraSure Technologies has obtained prequalification from the World Health Organisation (WHO) for its OraQuick HIV Self-Test (HIVST).
- Source: Medicaldevice-network-com
- 511
- July 26, 2017
Company Insight HIV Researches WHO
US researchers say blood test can detect Alzheimer’s early

Researchers at Washington University School of Medicine in St Louis, US, have carried out a study to identify a rapid and inexpensive test for Alzheimer’s disease.
- Source: Medical devices
- 446
- July 21, 2017
Alzheimer's Researches
Dune Medical’s MarginProbe destined for more than breast cancer, receives $12 million.

Dune Medical, which markets a tool that spots residual breast cancer cells following a lumpectomy, has raised $12.3 million. The funds will drive the development of the company’s technology for other types of cancer.
- Source: fiercebiotech
- 485
- July 10, 2017
breast cancer Market Views Researches
LifeArc teams up with UK defence lab and Canada’s CDRD

LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.
- Source: pharmatimes
- 589
- June 29, 2017
antibacterial LifeArc Market Views Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.